Recent developments of thromboxane modulators

Bibliography

• HAMBERG M, SVENSSON J, SAMUELSSON B: Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. ScL USA (1975) 72(8) :2994–2998.
   PubMed Web of Science ®Google Scholar
• ••Discovery of thromboxanes.
   Google Scholar
• ELLIS EF, OELZ 0, ROBERTS LJ etal: Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science (1976) 193(4258):1135–1137.
   PubMedGoogle Scholar
• PAWLOWSKI NA, KAPLAN G, HAMILLAL etal: Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures. J. Exp. Med. (1983) 158(2):393–412.
   Google Scholar
• GRANSTROM E, DICZFALUSY U, HAMBERG M et al: Thromboxane A2: biosynthesis and effects on platelets. Adv. Prostaglandin Thromboxane Leukot. Res. (1982) 10:15–58.
   PubMedGoogle Scholar
• NIE D, LAMBERTI M, ZACHAREK A etal: Thromboxane A2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun. (2000) 267(1):245–51. Recent discovery of possible implication of thromboxane in angiogenesis.
   Google Scholar
• DANIEL TO, LIU H, MORROW JD etal: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. (1999) 59(18):4574–4577.
   PubMed Web of Science ®Google Scholar
• ••Recent discovery of possible implication ofthromboxane in angiogenesis.
   Google Scholar
• HORNBY EJ, SKIDMORE IF: Evidencethat prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production. Biochem. PharmacoL (1982) 31(6): 1158–1160.
   PubMedGoogle Scholar
• COLEMAN RA, HUMPHREY PP, KENNEDY I etal: Comparison of the actions of U-46619, a prostaglandin H 2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br. J. PharmacoL (1981) 73(3):773–778.
   PubMedGoogle Scholar
• KENNEDY I, COLEMAN RA, HUMPHREY PP etal: Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins (1982) 24(5):667–689.
   PubMedGoogle Scholar
• •Classification of prostanoid receptors.
   Google Scholar
• MATS DE, SAUSSY DL Jr. CHAIKHOUNI A et al.: Pharmacologic characterization oh human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptor& J PhannacoL Exp. Ther. (1985) 233(2):418–24.
   Google Scholar
• HIRATA M, HAYASHI Y, USHIKUBI F et al.: Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature (1991) 349(6310):617–620.
   PubMedGoogle Scholar
• RAYCHOWDHURY MK, YUKAWA M, COLLINS LJ et al.: Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol. Chem. (1994) 269(30):19256–19261.
   PubMed Web of Science ®Google Scholar
• REILLY IA, DORAN JB, SMITH B et al.: Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation (1986) 73(6): 1300–1309.
   PubMed Web of Science ®Google Scholar
• FITZGERALD DJ, ROY L, CATELLA F et al.: Platelet activation in unstable coronary disease. N. Engl. J Med. (1986) 315(16):983–989.
   PubMed Web of Science ®Google Scholar
• HAMM CW, LORENZ RL, BL,EIFELD W et al.: Biochemical evidence of platelet activation in patients with persistent unstable angina. J. Am. Coll. Cardiol. (1987) 10(5):998–1006.
   Google Scholar
• WALSH SW: Preeclampsia: an imbalance inplacental prostacyclin and thromboxane production. Am. J. Obstet. GynecoL (1985) 152(3):335–340.
   PubMedGoogle Scholar
• IWAMOTO I, RA C, SATO T, TO MIOKAH et A: Thromboxane A2 production in allergen-induced immediate and late asthmatic responses. Its possible role in inducing the late response. J. Asthma (1988) 25(3):117–124.
   Google Scholar
• PATRONO C, CIABATTONI G, REMUZZI Get al.: Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. Clin. Invest. (1985) 76(3):1011–1018.
   Google Scholar
• SALDEEN TG, SALDEEN P, NICHOLS WW et al.: Increased production of thromboxane A2 by coronary arteries after thrombolysis. Am. Heart J. (1993) 125(2 Pt 1):277–284.
   Google Scholar
• DOGNE JM, DE LEVAL X, DELARGE J et al.: New trends in thromboxane and prostacyclin modulators. Curr. Med. Chem. (2000) 7(6):609–628.
   PubMedGoogle Scholar
• KATO K, OHKAWA S, TERAO S et A: Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. J. Med. Chem. (1985) 28(3):287–294.
   Google Scholar
• HECKER M, HAURAND M, ULLRICH V et al.: Spectral studies on structure-activity relationships of thromboxane synthase inhibitors. Eur. J. Biochem. (1986) 157(1):217–223.
   PubMedGoogle Scholar
• NEEDLEMAN P, RAZ A, FERRENDELLI JA et al.: Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc. Natl. Acad. Sci. USA (1977) 74(4):1716–1720.
   PubMedGoogle Scholar
• RANDALL MJ, PARRY MJ, HAWKES WOOD E et al.: UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb. Res. (1981) 23(1–2):145–162.
   Google Scholar
• HIRAKU S, TANIGUCHI K, WAKITANI K et al.: Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)pheny1]-2-propenoic acid (OKY-046). Jpn. J. Pharmacol. (1986) 41(3):393–401.
   PubMedGoogle Scholar
• UEMATSU T, NAGASHIMA S, INABA H et al.: Pharmacokinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers. J. Clin. Pharmacol. (1994) 34(1):41–47.
   PubMedGoogle Scholar
• PARRY MJ, RANDALL MJ, TYLER HM et al.: Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers. Lancet (1982) 17;2(8290):164.
   Google Scholar
• KU EC, MCPHERSON SE, SIGNOR C et al.: Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models. Biochem. Biophys. Res. Commun. (1983) 16;112(3):899–906.
   Google Scholar
• NAKASHIMA S, TABUCHI K, SHIMOKAWA S et al.: Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. NeuroL Med. Chir. (1998) 38(12):805–810.
   PubMed Web of Science ®Google Scholar
• OISHI M, MOCHIZUKI Y, HARA M et al.: Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction. Clin. Neuropharmacol. (1996) 19(6):526–531.
   PubMedGoogle Scholar
• ITOH H, YAMATANI K, OSHIDA N et al.: Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery. No To Shinkei (1998) 50(2): 147–155 .
   PubMedGoogle Scholar
• SEKI H, KUROMAKI K, TAKEDA S et al.: Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens. Pregnancy (1999) 18(2):157–164.
   PubMed Web of Science ®Google Scholar
• SEKI H, KUROMAKI K, TAKEDA S et al.: The possibility of clinical application of the thromboxane A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report. J. Obstet. Gynaecol. (1995) 21(4):357–365.
   Google Scholar
• FEUERSTEIN N, RAMWELL PW: OKY-1581, a potential selective thromboxane synthetase inhibitor. Eur. J. Pharmacol. (1981) 69(4):533–534.
   PubMedGoogle Scholar
• GORMAN RR, JOHNSON RA, SPILMAN CH et al.: Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3 -pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins (1983) 26(2):325–342.
   PubMedGoogle Scholar
• FIDDLER GI, LUMLEY P: Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. Circulation (1990) 81\(Suppl. 0:169–78.
   Google Scholar
• •Primary results of clinical trials with TXRAs and TXSIs.
   Google Scholar
• PATSCHEKE H, STEGMEIER K, MULLER-BECKMANN B et al.: Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Biomed. Biochim. Act. (1984) 43(8–9):S312–318.
   Google Scholar
• PATSCHEKE H, STEGMEIER K: Investigation on a selective non-pro stano ic thromboxane antagonist, BM 13.177, in human platelets. Thromb. Res. (1984) 33(3):277–288.
   Google Scholar
• STEGMEIER K, PILL J, MULLER-BECKMANN B et al: The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb. Res. (1984) 35 (4): 379–395.
   Google Scholar
• GRESELE P. DECKMYN H, ARNOUT J et al.: BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet (1984) 1(8384):991–994.
   Google Scholar
• SAMARA E, CAO G, LOCKE C et al.: Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. Clin. Pharmacol. Ther (1997) 62(4): 426–435.
   PubMedGoogle Scholar
• •Clinical trials with seratrodast.
   Google Scholar
• TAMAOKI J, K OND 0 M, NAKATA J etal: Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma. Chest (2000) 118(1):73–79.
   PubMed Web of Science ®Google Scholar
• TANAKA H, IGARASHI T, SAITOH T et al: Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients? Respir Med. (1999) 93(12):891–897.
   Google Scholar
• HARRIS DN, HEDBERG A, PHILLIPS MB et al: 7-Oxabicycloheptane analogs: modulators of the arachidonate cascade. Adv. Prostaglandin Thromboxane Leukot. Res. (1987) 17A:482–486.
   PubMedGoogle Scholar
• MONSHIZADEGAN H, HEDBERG A, WEBB ML: Characterization of binding of a specific antagonist, [3H]-SQ 29,548, to soluble thromboxane A2/prostaglandin H2 (TP) receptors in human platelet membranes. Life Sci. (1992) 51 (6) :431-437. open-chest rat. Naunyn. Schmiedebergs Arch. PharmacoL (1997) 356(4):462–466.
   Google Scholar
• SINGH J, SETH SD, MANCHANDA SC et al.: Protective actions of a thromboxane receptor antagonist, SQ 29548 on the ischemic myocardium: morphologic and hemodynamic effects. Prostaglandins Leukot. Essent. Fatty Acids (1997) 56(2):105–110.
   PubMedGoogle Scholar
• NAKANE M, REID JA, HAN WC et aL: 7-Oxabicyclo[2.2.1]heptyl carboxylic acids as thromboxane A, antagonists: aza omega-chain analogues. J. Med. Chem. (1990) 33(9):2465–2476.
   Google Scholar
• OGLETREE ML, HARRIS DN, SCHUMACHER WA et aL: Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane Aiprostaglandin endopenndde receptor antagonist. J. PharmacoL Exp. Ther.(1993) 264(2):570–578.
   PubMedGoogle Scholar
• NARISADA M, OHTANI M, WA TANABEF et aL: S3mthests and in vitro activity of various derivatives of a novel thromboxane receptor antagonist, (+/-)-(5Z) 7 [3 endo [(phenylsulfony1)-amino]bicyclo[2.2.1] hept-2-exo-yl]heptenoic acid. J. Med. Chem. (1988) 31(9):1847–1854.
   Google Scholar
• HAGISHITA S, SENO K. Thromboxane A, receptor antagonists. I. Synthesis and pharmacological activity of 7-oxabicyclo-[2.2.1]heptane derivatives with the benzenesulfonylamino group. Chem. Pharm. Bull. (1989) 37(2):327–335.
   Google Scholar
• FUJIMURAA, SHIGA T, KUMAGAI Y et al.: Pharmacokinetics of a new thromboxane A, receptor antagonist, S-1452, and its effect on platelet aggregation in healthy volunteers. J. Clin. Pharmacol. (1996) 36(5):409–413.
   PubMedGoogle Scholar
• DUBE GP, JAKUBOWSKI JA, BRUNE KA etal.: In vivo effects of a novel thromboxane Aiprostaglandin H (TXA2/ PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-y1Fheptenoic acid [(+)-S-145], on vascular, platelet and cardiac function. J. PharmacoL Exp. Ther. (1995) 272(2):799–807 .
   Google Scholar
• SHI H, YOKOYAMA A, KOHNO Net al.: Effect of thromboxane A, inhibitors on allergic pulmonary inflammation in mice. Eur. Respir. J. (1998) 11(3):624–629.
   Google Scholar
• YOSHIMI Y, FUJIMURA M, MYOU Set al.: Effect of thromboxane A(2) (TXA(2)) synthase inhibitor and TXA(2) receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs. Prostaglandins (2001) 65 (1): 1–9.
   Google Scholar
• TOHDAY, MURAKI M, KUBO H et al.: Role of chemical mediators in airway hyperresponsiveness in an asthmatic model. Respiration (2001) 68(1):73–77.
   PubMedGoogle Scholar
• LANE IF, LUMLEY P, MICHAEL MF et al.: A specific thromboxane receptor blocking drug, AH23848, reduces platelet deposition on vascular grafts in man. Thromb. Haemost. (1990) 64(3):369–373.
   PubMedGoogle Scholar
• SUTHERLAND MF, PARKINSON MM, HALLETT P: Teratogenicity of three substituted 4-biphenyls in the rat as a result of the chemical breakdown and possible metabolism of a thromboxane A,-receptor blocker. Teratology (1989) 39(6):537–545.
   PubMedGoogle Scholar
• HUMPHREY PP, HALLET P, HORNBY ET et al.: Pathophysiological actions of thromboxane A, and their pharmacological antagonism by thromboxane receptor blockade with GR32191. Circulation (1990) 81(1 Suppl):I42–52.
   Google Scholar
• BEASLEY RC, FEATHERSTONE RI, CHURCH MK et al.: Effect of a thromboxane receptor antagonist on PGD,-and allergen-induced bronchoconstriction. J. Appl. Physiol. (1989) 66(4):1685–1693.
   PubMed Web of Science ®Google Scholar
• EDMUNDS NJ, WOODWARD B: Effects of tumour necrosis factor-a on the coronary circulation of the rat isolated perfused heart: a potential role for thromboxane A, and sphingosine. Br. J. PharmacoL (1998) 124(3):493–498.
   PubMedGoogle Scholar
• KAWANO KI, HOKAMURA K, KOND 0 K et al.: Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding. Eur. J. PharmacoL (2001) 417(3):217–222.
   Google Scholar
• JANSSENS WJ, DECKMYN H, GRESELE P et al.: BM 13.177 selectively inhibits endoperwdde analogue induced vascular contractions. Arch. Int. Pharmacodyn. Ther. (1985) 276(1):28–34.
   Google Scholar
• MIKI I, KASE H, ISHII A: Differences in activities of thromboxane A, receptor antagonists in smooth muscle cells. Eur. J. Pharmacol. (1992) 227(2):199–204.
   PubMedGoogle Scholar
• ROALD HE, BARSTAD RM, ENGEN A et al.: HN-11500-a novel thromboxane receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb. Haemost. (1994) 71(1):103–109.
   PubMedGoogle Scholar
• BERTOLINO F, VALENTIN J P, PATOISEAU JF et al.: Evidence for partial agonist properties of daltroban (BM 13,505) at TP receptors in the anaesthetized A2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis. Acta Otolaryngol. Suppl (1998) 537:32–37.
   PubMedGoogle Scholar
• SHINOZAKI K, SATO H, IVVAKUMA T et al.: Synthesis and thromboxane antagonistic activity activity of indane derivatives. Bioorg. Med. Chem. Lett. (1999) 9(3):401–406.
   PubMedGoogle Scholar
• lANAKAT,ITOS,HIGASHINORetaL: A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Thromb. Res. (1998) 91(5):229–235.
   PubMedGoogle Scholar
• TANAKA T, SATO R, KURIMOTO T: Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. Eur. J. PharmacoL (2000) 401(3):413–418.
   PubMedGoogle Scholar
• DEPIN JC, VIGIE A, CHAVERNAC G et al.: Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A, receptor antagonist sodium 4-[[1-[[[(4- chlorophenyl)sulfonyl]amino]methyl]cyclo pentyl] methyl]benzeneacetate. Arzneimittelforschung (1994) 44(11):1203–1207.
   PubMedGoogle Scholar
• FIEDLERVB, PERZBORN E, SEUTER F et al.: Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenyl-sulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid. Arzneimittelforschung (1989) 39(12):1527–1530.
   PubMedGoogle Scholar
• SEUTER F, PERZBORN E, ROSENTRETER U et al.: Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid. Arzneimittelforschung (1989) 39(12):1525–1527.
   PubMedGoogle Scholar
• PERZBORN E, SEUTER F, FIEDLERVB et al.: Action of the novel selective thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid on vascular smooth muscle preparations. Arzneimittelforschung (1989) 39(12) :1522–1525.
   PubMed Web of Science ®Google Scholar
• AIZAWA H, SHIGYO M, NOGAMI H et al.: BAYU3405, a thromboxane antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest (1996) 109(2):338–342.
   PubMed Web of Science ®Google Scholar
• TERADAN,Y1MAKOSHIT, HASEGAWA M et al.: The effect of ramatroban (BAYU3405), a thromboxane J. Pharmacol. (1998) 78(4):479–486.
   Google Scholar
• ESCOLAR G, ALBORS M, GARRIDO M et al.: Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: potentiation of antiplatelet effects of aspirin. Eur. J. Clin. Invest. (1998) 28(7):562–568.
   PubMedGoogle Scholar
• CISSE-THIAM M, DROUET L: Comparative study of the antrthrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor. Dakar Med. (1999) 44(1):25–27.
   PubMedGoogle Scholar
• KARASAWA A, KAWAKAGE M, SHIRAKURA S etal. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-1142-(5,6-dimethy1-1-benzimidazoly1)-ethylidene]-6,11-dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate. Arzneimittelforschung (1991) 41(12) :1230–12 36.
   Google Scholar
• IMURA Y, TERASHITA Z, SHIBOUTA Y etal.: Antagonistic action of AA-24I4 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels. Jpn. I Pharmacol. (1990) 52(I):35–43.
   Google Scholar
• GRESELE P. ARNOUT J, DECKMYN H et al: Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J. Clin. Invest. (1987) 80(5):1435–1445.
   Google Scholar
• Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation (1994) 89(2):588–595. Clinical trial with ridogrel versus aspirin.
   Google Scholar
• NARAN NH, CHETTY N: The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic Type Ha subjects. Thromb. Res. (1997) 88(5):399–407.
   PubMedGoogle Scholar
• QUEST DW, WILSON TW: Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat Jpn. J. Pharmacol. (1998) 78(4):479–486.
   Google Scholar
• SOYKA R, GUTH BD, WEISENBERGER HM et al.: Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J. Med. Chem. (1999) 42(7):1235–1249.
   PubMedGoogle Scholar
• POGLIANI E, MILANI M: Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study. J. Int. Med. Res. (1996) 24(3) :311-315. Clinical trial with picotamide.
   Google Scholar
• MILANI M, LONGONI A, MADERNA M: Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br. Clin. Pharmacol. (1996) 42(6):782–785. Clinical trial with picotamide.
   Google Scholar
• COTO V. OLIVIERO U, COCOZZA M et al: Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study. J. Int. Med. Res. (1998) 26(4):200–205.
   PubMedGoogle Scholar